Baker BROS. Advisors LP Decreases Stake in Hookipa Pharma Inc (NASDAQ:HOOK)

Baker BROS. Advisors LP lessened its position in shares of Hookipa Pharma Inc (NASDAQ:HOOK) by 90.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 812,814 shares of the company’s stock after selling 7,315,337 shares during the period. Baker BROS. Advisors LP owned about 6.74% of Hookipa Pharma worth $3,495,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Virtu Financial LLC acquired a new position in shares of Hookipa Pharma during the first quarter worth $31,000. Renaissance Technologies LLC lifted its holdings in Hookipa Pharma by 38.4% during the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after buying an additional 83,800 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in Hookipa Pharma by 12.3% during the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock worth $586,000 after buying an additional 108,844 shares during the last quarter. 63.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on HOOK shares. Royal Bank of Canada dropped their price objective on Hookipa Pharma from $50.00 to $48.00 and set an “outperform” rating on the stock in a report on Friday, November 15th. JMP Securities dropped their price target on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 21st.

Hookipa Pharma Price Performance

NASDAQ HOOK opened at $2.52 on Monday. The company has a fifty day moving average of $3.61 and a two-hundred day moving average of $5.28. Hookipa Pharma Inc has a 1 year low of $2.08 and a 1 year high of $11.30. The company has a market capitalization of $30.39 million, a PE ratio of -0.68 and a beta of 0.84.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.